Effect of A-lanata leaf extract and Vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria

被引:108
作者
Selvam, R [1 ]
Kalaiselvi, P [1 ]
Govindaraj, A [1 ]
Murugan, VB [1 ]
Kumar, ASS [1 ]
机构
[1] Univ Madras, Dr Alm PG Inst Basic Med Sci, Dept Biochem Med, Chennai 600021, India
关键词
Vediuppu chunnam; Aerva lanata; urinary risk factors; hyperoxaluria; calcium oxalate supersaturation;
D O I
10.1006/phrs.2000.0745
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Urolithiasis is one of the third most common afflictions found in humans. The efficacy of the two Siddha drugs, Aerva lanata and Vediuppu chunnam as antilithic agents using a urolithic rat model were tested in this study. Hyperoxaluria was induced in rats using 0.75% ethylene glycol in drinking water. Aerva lanata (3.0 mg kg(-1) body weight) and Vediuppu chunnam (3.5 mg kg(-1) body weight) were given orally for 28 days. Urinary risk factors of urolithiasis were monitored at the end of 7th, 14th: 21st and 28th days. Urinary volume was increased in hyperoxaluric as well as drug-treated rats. Increased urinary excretion of calcium, oxalate, uric acid, phosphorus and protein in hyperoxaluric rats was brought down significantly by the administration of A. lanata or Vediuppu chunnam. Decreased magnesium excretion in hyperoxaluric rats was normalized by drug treatment. The drug increases the urine volume, thereby reducing the solubility product with respect to calcium oxalate and other crystallizing salts such as uric acid, which may induce epitaxial deposition of calcium oxalate. Drug alone treated rats did not show any adverse effects. Combination therapy was found to be more effective and this indigenous medicine can be used successfully as an antilithic agent. (C) 2001 Academic Press.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 30 条
[1]
AECKART KSJ, 1989, UROL RES, V17, P3
[2]
Anand R, 1991, P 24 25 PHARM SOC C, pA
[3]
Repeated urine analysis in patients with calcium stone disease [J].
Bek-Jensen, H ;
Tiselius, HG .
EUROPEAN UROLOGY, 1998, 33 (03) :323-332
[4]
Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers [J].
BekJensen, H ;
Tiselius, HG .
UROLOGICAL RESEARCH, 1997, 25 (05) :365-372
[5]
Caraway WT, 1963, STANDARD METHODS CLI, V4, P239
[6]
RANDOMIZED TRIAL OF ALLOPURINOL IN THE PREVENTION OF CALCIUM-OXALATE CALCULI [J].
ETTINGER, B ;
TANG, A ;
CITRON, JT ;
LIVERMORE, B ;
WILLIAMS, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (22) :1386-1389
[7]
URINE COMPOSITION IN NORMAL SUBJECTS AFTER ORAL INGESTION OF OXALATE-RICH FOODS [J].
FINCH, AM ;
KASIDAS, GP ;
ROSE, GA .
CLINICAL SCIENCE, 1981, 60 (04) :411-418
[8]
Fiske CH, 1925, J BIOL CHEM, V66, P375
[9]
INHIBITORY EFFECT OF PYROPHOSPHATE, CITRATE, MAGNESIUM AND CHONDROITIN SULFATE IN CALCIUM-OXALATE UROLITHIASIS [J].
GRASES, F ;
GENESTAR, C ;
CONTE, A ;
MARCH, P ;
COSTABAUZA, A .
BRITISH JOURNAL OF UROLOGY, 1989, 64 (03) :235-237
[10]
DISSOLVED URATE PROMOTES CALCIUM-OXALATE CRYSTALLIZATION - EPITAXY IS NOT THE CAUSE [J].
GROVER, PK ;
RYALL, RL ;
MARSHALL, VR .
CLINICAL SCIENCE, 1993, 85 (03) :303-307